Activest Wealth Management’s Protalix BioTherapeutics PLX Stock Holding History

Activest Wealth Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$699	Hold	300	–	–	﹤0.01%	1014
2026 Q1	$651	Hold	300	–	–	﹤0.01%	1060
2025 Q4	$540	Hold	300	–	–	﹤0.01%	994
2025 Q3	$666	Hold	300	–	–	﹤0.01%	934
2025 Q2	$444	Hold	300	–	–	﹤0.01%	879
2025 Q1	$768	Hold	300	–	–	﹤0.01%	801
2024 Q4	$564	Hold	300	–	–	﹤0.01%	520
2024 Q3	$306	Hold	300	–	–	﹤0.01%	504
2024 Q2	$351	Buy	+300	New	+$354	﹤0.01%	475

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Activest Wealth Management's PLX Position: Q2 2026 in Review

Activest Wealth Management held its Protalix BioTherapeutics (PLX) position steady in Q2 2026 at 300 shares worth $699. The position accounts for ﹤0.01% of the portfolio, ranked #1014.

Activest Wealth Management first reported a position in PLX in Q2 2024 and has held it in 9 quarters since. The position peaked at $768 in Q1 2025. 101 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Activest Wealth Management held 300 shares of Protalix BioTherapeutics worth $699 as of Q2 2026.
Activest Wealth Management left its Protalix BioTherapeutics share count unchanged in Q2 2026.
Protalix BioTherapeutics made up ﹤0.01% of Activest Wealth Management's portfolio in Q2 2026, its #1014 holding.
Activest Wealth Management first reported a position in Protalix BioTherapeutics in Q2 2024 and has held it in 9 quarters since.
Activest Wealth Management's Protalix BioTherapeutics position peaked at $768 in Q1 2025.
101 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Activest Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.